Edition:
United States

Agile Therapeutics Inc (AGRX.OQ)

AGRX.OQ on NASDAQ Stock Exchange Global Market

0.96USD
19 Oct 2018
Change (% chg)

$0.12 (+14.37%)
Prev Close
$0.84
Open
$0.82
Day's High
$0.97
Day's Low
$0.79
Volume
691,532
Avg. Vol
515,672
52-wk High
$5.32
52-wk Low
$0.23

Chart for

About

Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company's lead product candidate is Twirla, also known as... (more)

Overall

Beta: 1.32
Market Cap(Mil.): $15.88
Shares Outstanding(Mil.): 34.38
Dividend: --
Yield (%): --

Financials

  AGRX.OQ Industry Sector
P/E (TTM): -- 119.85 32.14
EPS (TTM): -0.76 -- --
ROI: -80.65 1.96 12.83
ROE: -92.14 1.12 14.95

Agile Therapeutics sinks after FDA feedback on contraceptive

Agile Therapeutics Inc's shares sank 75 percent on Friday after the drug developer said it expects to pursue what could be a prolonged appeal against health regulators' issues over its chief experimental product, a contraceptive patch.

May 18 2018

UPDATE 2-Agile Therapeutics sinks after FDA feedback on contraceptive

* FDA suggests additional study of contraceptive may be needed

May 18 2018

Agile Therapeutics exploring funding options after FDA meeting

May 18 Agile Therapeutics Inc said on Friday it was looking for ways to fund operations after a meeting with the U.S. health regulator raised the possibility of a new clinical trial to test its stick-on contraceptive patch, Twirla.

May 18 2018

BRIEF-Agile Therapeutics Provides Regulatory Update On Twirla® (Ag200-15) For The Prevention Of Pregnancy

* AGILE THERAPEUTICS, INC. PROVIDES REGULATORY UPDATE ON TWIRLA® (AG200-15) FOR THE PREVENTION OF PREGNANCY

May 18 2018

BRIEF-Agile Therapeutics Reports Q1 Loss Per Share $0.20

* AGILE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 07 2018

Earnings vs. Estimates